心血管康复医学杂志
心血管康複醫學雜誌
심혈관강복의학잡지
Chinese Journal of Cardiovascular Rehabilitation Medicine
2015年
5期
547-550
,共4页
李伟红%李英霞%金艺华%李艳美
李偉紅%李英霞%金藝華%李豔美
리위홍%리영하%금예화%리염미
利钠肽 ,脑%呼吸困难%诊断 ,鉴别
利鈉肽 ,腦%呼吸睏難%診斷 ,鑒彆
리납태 ,뇌%호흡곤난%진단 ,감별
Natriuretic peptide,brain%Dyspnea%Diagnosis,differential
目的:探讨脑钠肽(BNP)和N末端脑钠肽前体(NT‐proBNP)的含量变化对呼吸困难患者的鉴别诊断价值。方法:选择入院时呼吸困难患者150例,分为心源性呼吸困难组(心源性组,51例),肺源性呼吸困难组(肺源性组,47例)和肺源性呼吸困难加心源性呼吸困难组(心肺源性组,52例)。另选择正常体检者40例作为正常对照组。观察比较各组治疗前后BNP和NT‐proBNP的含量。结果:治疗前,与正常对照组比较,心源性组,心肺源性组和肺源性组的血浆BNP和NT‐proBNP含量均显著升高,且心源性组的显著高于肺源性组和心肺源性组,心肺源性组的显著高于肺源性组的, P均<0.01;治疗前心源性组,心肺源性组,肺源性组的NT‐proBNP含量依次为[(3356.6±321.2) pg/ml比(3156.9±239.8) pg/ml比(2563.7±234.20) pg/ml],组间比较 P均<0.01;出院1周后,3组的血浆BNP和NT‐proBNP含量均较治疗前显著降低,仍是心源性组的BNP含量最高,肺源性组的最低,心肺源性组的居中,组间比较, P均<0.01。结论:血浆BNP和NT‐proBNP含量有助于鉴别诊断呼吸困难是否属于心源性或肺源性疾病。
目的:探討腦鈉肽(BNP)和N末耑腦鈉肽前體(NT‐proBNP)的含量變化對呼吸睏難患者的鑒彆診斷價值。方法:選擇入院時呼吸睏難患者150例,分為心源性呼吸睏難組(心源性組,51例),肺源性呼吸睏難組(肺源性組,47例)和肺源性呼吸睏難加心源性呼吸睏難組(心肺源性組,52例)。另選擇正常體檢者40例作為正常對照組。觀察比較各組治療前後BNP和NT‐proBNP的含量。結果:治療前,與正常對照組比較,心源性組,心肺源性組和肺源性組的血漿BNP和NT‐proBNP含量均顯著升高,且心源性組的顯著高于肺源性組和心肺源性組,心肺源性組的顯著高于肺源性組的, P均<0.01;治療前心源性組,心肺源性組,肺源性組的NT‐proBNP含量依次為[(3356.6±321.2) pg/ml比(3156.9±239.8) pg/ml比(2563.7±234.20) pg/ml],組間比較 P均<0.01;齣院1週後,3組的血漿BNP和NT‐proBNP含量均較治療前顯著降低,仍是心源性組的BNP含量最高,肺源性組的最低,心肺源性組的居中,組間比較, P均<0.01。結論:血漿BNP和NT‐proBNP含量有助于鑒彆診斷呼吸睏難是否屬于心源性或肺源性疾病。
목적:탐토뇌납태(BNP)화N말단뇌납태전체(NT‐proBNP)적함량변화대호흡곤난환자적감별진단개치。방법:선택입원시호흡곤난환자150례,분위심원성호흡곤난조(심원성조,51례),폐원성호흡곤난조(폐원성조,47례)화폐원성호흡곤난가심원성호흡곤난조(심폐원성조,52례)。령선택정상체검자40례작위정상대조조。관찰비교각조치료전후BNP화NT‐proBNP적함량。결과:치료전,여정상대조조비교,심원성조,심폐원성조화폐원성조적혈장BNP화NT‐proBNP함량균현저승고,차심원성조적현저고우폐원성조화심폐원성조,심폐원성조적현저고우폐원성조적, P균<0.01;치료전심원성조,심폐원성조,폐원성조적NT‐proBNP함량의차위[(3356.6±321.2) pg/ml비(3156.9±239.8) pg/ml비(2563.7±234.20) pg/ml],조간비교 P균<0.01;출원1주후,3조적혈장BNP화NT‐proBNP함량균교치료전현저강저,잉시심원성조적BNP함량최고,폐원성조적최저,심폐원성조적거중,조간비교, P균<0.01。결론:혈장BNP화NT‐proBNP함량유조우감별진단호흡곤난시부속우심원성혹폐원성질병。
Objective:To explore differential diagnosis value of changes of brain natriuretic peptide (BNP) and N ter‐minal pro brain natriuretic peptide (NT‐proBNP) concentrations in patients with dyspnea .Methods :A total of 150 patients with dyspnea at hospitalization were enrolled and divided into cardiogenic dyspnea group (CD group ,n=51) ,pulmonary dyspnea group (PD group ,n=47) and cardiogenic plus pulmonary dyspnea group (CPD group ,n=52) .Another 40 healthy subjects were regarded as normal control group .Concentrations of BNP and NT‐proBNP were observed and compared among all groups before and after treatment .Results:Before treatment ,compared with normal control group , there were significant rise in plasma concentrations of BNP and NT‐proBNP in CD group ,CPD group and PD group ,that of CD group was significantly higher than those of PD group and CPD group , and that of CPD group was significantly higher than that of PD group , P<0.01 all .Before treatment ,the NT‐proBNP content in CD group ,CPD group , PD group were [ (3356.6 ± 321.2) pg/ml vs . (3156.9 ± 239.8) pg/ml vs .(2563.7 ± 234.20) pg/ml] respectively , comparison among three groups , P<0.01 all .Compared with before treatment ,one week after discharge ,plasma concentrations of BNP and NT‐proBNP significantly reduced in CD group ,CPD group and PD group ,the plasma BNP and NT‐proBNP concentrations of CD group were the highest , those of PD group were the lowest ,and those of CPD group were the middle , P<0.01 all .Conclusion:Plasma BNP and NT‐proBNP concentrations are helpful to differential diagnose whether dyspnea belongs to cardiogenic or pul‐monary diseases .